Taiho invests in Arcus Biosciences as part of $70 million deal
pharmafile | September 6, 2016 | News story | Manufacturing and Production, Sales and Marketing | Arcus, investment, taiho
Taiho Ventures has invested in California-based Arcus Biosciences alongside GV, Invus, DROIA Oncology Ventures and Stanford University as part of a $70 million series B investment round.
Series A investors include The Column Group, Foresite Capital, Novartis and Celgene.
The funding enables Arcus to continue its rapid drug development activities for the company’s small molecule and antibody immuno-oncology approaches with the goal of building its own internal combinations.
“Taiho Ventures is pleased to support the Arcus team and its promising drug pipeline programmes,’ said Nobuyuki Hashimoto, executive director, board member and global chief corporate officer at Taiho Pharmaceutical.
“Terry Rosen, chief executive officer, and Juan Jaen, president, are among the leaders in the oncology drug discovery field with more than 20 years of experience, and have built an innovative immuno-oncology programme at Flexus, leading to the significant acquisition transaction with Bristol-Myers Squibb in a short period of time,” he continued. “Together, they have many years of industry experience as successful entrepreneurs and are invaluable as they take Arcus to the next level with this significant round of financing.
“The addition of Taiho Ventures to this round of investment will augment the financial and business resources available to Arcus to help build a successful company in the immuno-oncology space, in particular, looking at the Japan and Asian market. They have significant experience in the industry and will provide guidance in the company’s Japan/Asian strategic direction.”
Matt Fellows
Related Content
Apiary invests in life sciences SEO pioneer PIO to support global expansion
Private equity firm Apiary Capital has invested in performance-io (PIO), a specialist life sciences performance …
Amferia closes €1,2 million investment to combat resistant bacterial infections
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its …
Novo Holdings Invests in Oxford Nanopore Technologies
leading life science investor Novo Holdings, announced a £50m investment in Oxford Nanopore Technologies. Oxford …
